Loading page…

Report overview

The report describes Mycenax's 2022 transition and expansion as a biologics CDMO, with GMP Plant 2 commencing operations and investments in ADC and cell-therapy capabilities. Operating revenue was NT$732,276 thousand, while technical service income reached NT$614,857 thousand and represented 84% of 2022 revenue. Environmental disclosures report 1,566 metric tons of CO2 equivalent, 21.695 tonnes of waste and 16,399 tonne of water consumption. The company also describes sustainability coordination by the Administration Management Division, with results reported to the board.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Publication date: 22 April 2023
Language
Pages
File size

Standards & Assurance

Standards

Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Scope 1 emissions
Scope 2 emissions
Water consumption
Waste
Employees
Women on the board
Workplace fatalities

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services